Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980995 | 0.89 | NPC1 (0.42) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL23987478 | 0.84 | S1PR1 (0.48) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL19968516 | 0.84 | S1PR1 (0.51) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL2230216 | 0.81 | AKT1 (0.40) | ALDH1A1AKT1PIK3CAMTORBTK | |
| SCHEMBL744274 | 0.81 | AKT1 (0.40) | ALDH1A1AKT1PIK3CAMTORBTK | |
| SCHEMBL2226844 | 0.81 | AKT1 (0.40) | ALDH1A1AKT1PIK3CAMTORBTK | |
| SCHEMBL21153243 | 0.79 | PRKCZ (0.52) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL19968732 | 0.75 | NPC1 (0.48) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL16592531 | 0.74 | RAB9A (0.74) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 | |
| SCHEMBL29936657 | 0.74 | RAB9A (0.74) | NPC1RAB9AS1PR1SMN1; SMN2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | NPC1 1749/4885RAB9A 4715/4885S1PR1 3916/4885 |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | VNN1, NGLY1, NUCB2 | NPC1 1749/4885RAB9A 4715/4885S1PR1 3916/4885 |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | NPC1 1749/4885RAB9A 4715/4885S1PR1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.